Key result
LVADs improve survival and quality of life in Stage D HFrEF, despite frequent adverse events.
Why the study?
Left ventricular assist devices are an increasingly prevalent therapy for Stage D heart failure with reduced ejection fraction, frequently serving as a substitute for cardiac transplantation due to continuing organ donor shortages, although device-related adverse events remain common.
Left ventricular assist devices improve survival and quality of life in Stage D heart failure with reduced ejection fraction, frequently serving as a substitute for cardiac transplantation amid organ donor shortages.
LVAD decisions in advanced HF should remain individualized; level 5 evidence leaves open optimal patient selection and timing.
Left ventricular assist devices are becoming an increasingly prevalent therapy for patients with Stage D heart failure with reduced ejection fraction. Technological advances have improved the durability of these devices and have significantly lengthened survival in these patients. Quality of life is also improved, although adverse events related to device therapy remain common. Nevertheless, with the continuing organ donor shortage for cardiac transplantation, left ventricular assist devices are frequently serving as a substitute for transplant, particularly in the elderly patient.
No takes yet. Share an insight, caveat, or question.
MANCINI et al. (2015) conducted a review in Stage D heart failure with reduced ejection fraction. Left ventricular assist devices vs. Cardiac transplantation was evaluated on Survival and quality of life. Left ventricular assist devices significantly lengthen survival and improve quality of life in Stage D heart failure with reduced ejection fraction, though adverse events remain common.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: